Heat Biologics seeks FDA nod to test bladder cancer candidate

10/3/2013 | Pharmaceutical Business Review Online

Heat Biologics submitted an investigational new drug application to the FDA for approval to test its second drug candidate, HS-410, in patients with bladder cancer. Heat announced that the HS-410 program and all of the firm's clinical trials will be supervised by Melissa Price, the company's new vice president of clinical and regulatory affairs.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC